SK Plasma Ships First Products Made from Indonesian Plasma

Supplying Essential Medicines Through Contract Manufacturing Until Local Production Facilities Are Established

SK Plasma has shipped plasma fractionation products produced using blood plasma from Indonesian nationals for the first time.

Kim Seungjoo, CEO of SK Plasma (fifth from the left), and Chethep Herawan, Ambassador of Indonesia (fourth from the left), along with SK Plasma and Indonesian government officials, are posing for a commemorative photo at the inaugural shipment ceremony of plasma fractionation products held on the 2nd at the SK Plasma Andong Plant. SK Plasma

SK Plasma announced on December 4 that it had completed the inaugural shipment of finished plasma fractionation products manufactured using Indonesian plasma at its Andong plant in North Gyeongsang Province on December 2. The commemorative ceremony was attended by company representatives including Kim Seungjoo, CEO of SK Plasma, Chethep Herawan, Indonesian Ambassador to Korea, and Reza Mawastama, Head of the Indonesia Investment Promotion Center (IIPC).

Until now, Indonesia has relied entirely on imports for plasma fractionation products, making this the first time such products produced from plasma donated by Indonesian nationals will be supplied domestically.

The shipment and exclusive supply of finished products made from Indonesian plasma follows the Indonesian Ministry of Social Affairs’ designation in 2023 of SK Plasma’s local joint venture, SK Plasma Core Indonesia, as the operator of the “Plasma Fractionation Product Self-Sufficiency Project.” At that time, it was agreed that, until local production infrastructure was established, finished products would be supplied to Indonesia through contract manufacturing (CMO) using plasma from Indonesian nationals.

Accordingly, in April, the Indonesian side sent plasma to SK Plasma, which then carried out key processes such as fractionation and purification at the Andong plant to produce albumin and immunoglobulin. Starting with this initial export, SK Plasma plans to contract-manufacture approximately 300,000 liters of plasma until the local infrastructure becomes commercially operational, thereby continuously supporting the Indonesian government’s supply of essential medicines.

Chethep Herawan, Indonesian Ambassador to Korea, stated, “Thanks to SK Plasma’s technological capabilities, we are now able to produce essential medicines for our people using plasma donated by Indonesians. Beyond CMO, we will continue to strengthen our collaboration to internalize plasma fractionation production technology and further enhance our self-sufficiency.”

Kim Seungjoo, CEO of SK Plasma, said, “During the infrastructure construction period, we will train personnel to operate the local plant and contribute to the expansion of plasma centers. Along with CMO supply, we will devote company-wide efforts to ensure that Indonesia’s self-sufficiency infrastructure is established and operational as quickly as possible, including facility construction and preliminary training for technology transfer.”

SK Plasma is currently building a plasma fractionation plant in the Karawang Industrial Complex in Jakarta with an annual capacity of 600,000 liters, targeting the start of commercial production in 2027. Recently, the company has also expanded its global business by signing a shareholders’ agreement with the Turkish government and the Turkish Red Crescent (Kizilay, the equivalent of the Red Cross in Islamic countries) for a plasma fractionation product localization project, securing a 15% stake.

This content was produced with the assistance of AI translation services.